OtherPerspective
P-Glycoprotein—a Clinical Target in Drug-Refractory Epilepsy?
Robert W. Robey, Alberto Lazarowski and Susan E. Bates
Molecular Pharmacology May 2008, 73 (5) 1343-1346; DOI: https://doi.org/10.1124/mol.108.046680
Robert W. Robey
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (R.W.R., S.E.B.); and Clinical Biochemistry Department, School of Pharmacy and Biochemistry (A.L.) and E. de Robertis Neuroscience Research Institute (A.L.), University of Buenos Aires, Argentina
Alberto Lazarowski
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (R.W.R., S.E.B.); and Clinical Biochemistry Department, School of Pharmacy and Biochemistry (A.L.) and E. de Robertis Neuroscience Research Institute (A.L.), University of Buenos Aires, Argentina
Susan E. Bates
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (R.W.R., S.E.B.); and Clinical Biochemistry Department, School of Pharmacy and Biochemistry (A.L.) and E. de Robertis Neuroscience Research Institute (A.L.), University of Buenos Aires, Argentina
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
OtherPerspective
P-Glycoprotein—a Clinical Target in Drug-Refractory Epilepsy?
Robert W. Robey, Alberto Lazarowski and Susan E. Bates
Molecular Pharmacology May 1, 2008, 73 (5) 1343-1346; DOI: https://doi.org/10.1124/mol.108.046680
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement